U
ASMB icon

UBS’s Assembly Biosciences ASMB Stock Holding History

UBS’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-371
Closed -$26.3K – 10393
2014
Q1 		$28K Buy
371
+351
+1,755% +$54.7K ﹤0.01% 7627
2013
Q4 		$5K Sell
20
-171
-90% -$31.1K ﹤0.01% 9530
2013
Q3 		$33K Buy
191
+29
+18% +$4.44K ﹤0.01% 7403
2013
Q2 		$23K Buy
+162
New +$25.4K ﹤0.01% 7709

Other funds holding ASMB

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS's ASMB Position: Q2 2014 in Review

UBS sold out of Assembly Biosciences (ASMB) in Q2 2014, closing a stake of 371 shares — an estimated $26.3K sold.

UBS first reported a position in ASMB in Q2 2013 and held it in 4 quarters. The position peaked at $33K in Q3 2013. 27 funds tracked by Wall St. Rank hold ASMB as of Q2 2014.

  • UBS reported no remaining Assembly Biosciences position as of Q2 2014 after selling out during the quarter.
  • UBS sold 371 Assembly Biosciences shares in Q2 2014, an estimated $26.3K.
  • UBS first reported a position in Assembly Biosciences in Q2 2013 and held it in 4 quarters.
  • UBS's Assembly Biosciences position peaked at $33K in Q3 2013.
  • 27 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.